Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer
- 17 January 2006
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 58 (3) , 285-291
Abstract
Purpose: We conducted a phase I study to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of weekly docetaxel and cisplatin (DOC/CDDP) with concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC). Materials and methods: The DOC/CDDP administration schedules consisted of a split schedule (SS) with administration in 3 out of every 4 weeks, and a continuous schedule (CS) with administration every week. TRT was given to a total dose of 60 Gy at 2 Gy per fraction over 6 weeks. Results: Twenty-one patients entered the study. The patient characteristics were: PS 0/1/2, 6/13/2; Sq/Ad, 16/5; stage IIIA/IIIB, 4/17. The principal DLT was grade3 esophagitis. The MTD of DOC on the SS and CS in combination with CDDP (25 mg/m2/week) was 25 and 20 mg/m2/week, respectively. We determined the RD and schedule of DOC/CDDP on the SS to be 20/25 mg/m2/week. The serum α-1-acid glycoprotein (AAG) concentration values were found to be negatively correlated with the grade of esophagitis. The median survival time was 23.1 months. Conclusion: The chemoradiation regimen tested in this study has promising activity and manageable toxicity. The continuous schedule could not be recommended due to excessive toxicity. The main DLT was esophagitis, and it significantly correlated with the plasma AAG concentration.Keywords
This publication has 22 references indexed in Scilit:
- Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancerBritish Journal of Cancer, 2003
- Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung CancerChest, 2000
- Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 TrialJNCI: Journal of the National Cancer Institute, 1996
- Docetaxel serum protein binding with high affinity to alpha1-acid glycoproteinInvestigational New Drugs, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Taxol and ionizing radiation: Interaction and mechanismsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994
- Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung CancerNew England Journal of Medicine, 1992
- Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell linesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 PatientsJNCI: Journal of the National Cancer Institute, 1991
- Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical dataInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1987